BPBenjamin Peter

Benjamin Peter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Peter has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline Pot

    Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

    2 shared publications
  • Dominique Velin

    Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

    2 shared publications
  • Ana Alcaraz-Serna

    Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

    1 shared publication
  • Chantal Desponds

    Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland

    1 shared publication
  • Christine Kowalczyk-Quintas

    Department of Immunobiology, University of Lausanne, Epalinges 1066, Switzerland

    1 shared publication
  • Clémentine Gaillard

    Service of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland

    1 shared publication

Latest Publications

  • Open Access

    Helicobacter pylori infection reduces cancer immunotherapy efficacy through hepatic urea cycle activation and creatine depletion

    by Benjamin Peter, Marco Ongaro, Lukas F Mager, Kevin Rochat, Clémentine Gaillard, Nathan Breuillard, Martin Poms, Coralee Serex, Sebastien Godat, Olivier Braissant, et al.

    Background Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients. Increasing evidence implicates the gut microbiota in modulating ICI responses. We previously identified Helicobacter pylori infection as a negative predictor of ICI efficacy.Objective Here, we aimed to elucidate the metabolic mechanisms by which H. pylori impairs antitumour immunity and to evaluate creatine supplementation as a potential therapeutic intervention.Design Using murine models of neonatal H. pylori infection and cancer immunotherapy, we conducted targeted plasma metabolomics, hepatic gene and protein expression profiling and isotope tracing to delineate infection-induced metabolic alterations. Functional assays were used to assess the impact of creatine on CD8+ T cell activation in vitro and in vivo, including CRISPR-Cas9-mediated knockdown of the creatine transporter Slc6a8.Results Neonatal H. pylori infection accelerated the hepatic urea cycle, resulting in systemic depletion of creatine and its precursors. Creatine supplementation restored antitumour immunity in infected mice in a CD8+ T cell-dependent manner. Mechanistically, creatine increased the frequency of tumour-specific effector and effector memory CD8+ T cells in tumour-draining lymph nodes and enhanced the population of tumour-infiltrating T cell factor-1⁻ (TCF-1) granzyme B+ effector CD8+ T cells.Conclusion H. pylori drives metabolic reprogramming that undermines ICI efficacy through creatine depletion and CD8+ T cell dysfunction. Creatine supplementation may offer a promising adjuvant approach to overcome H. pylori-associated resistance to cancer immunotherapy.

  • T cell receptor precision editing of regulatory T cells for celiac disease

    by Raphaël Porret, Ana Alcaraz-Serna, Benjamin Peter, Jeremiah Bernier-Latmani, Rebecca Cecchin, Oscar Alfageme-Abello, Laura Ermellino, Morteza Hafezi, Eleonora Pace, M. Fleur du Pré, et al.

    Celiac disease, a gluten-sensitive enteropathy, demonstrates a strong human leukocyte antigen (HLA) association, with more than 90% of patients carrying the HLA-DQ2.5 allotype. No therapy is available for the condition except for a lifelong gluten-free diet. To address this gap, we explored the therapeutic potential of regulatory T cells (T regs ). By orthotopic replacement of T cell receptors (TCRs) through homology-directed repair, we generated gluten-reactive HLA-DQ2.5–restricted CD4 + engineered (e) T effector cells (T effs ) and eT regs and performed in vivo experiments in HLA-DQ2.5 transgenic mice. Of five validated TCRs, TCRs specific for two immunodominant and deamidated gluten epitopes (DQ2.5-glia-α1a and DQ2.5-glia-α2) were selected for further evaluation. CD4 + eT effs exposed to deamidated gluten through oral gavage colocalized with dendritic and B cells in the Peyer’s patches and gut-draining lymph nodes and specifically migrated to the intestine. The suppressive function of human eT regs correlated with high TCR functional activity. eT regs specific for one epitope suppressed the proliferation and gut migration of CD4 + eT effs specific for the same and the other gluten epitope, demonstrating bystander suppression. The suppression requires an antigen-specific activation of eT regs given that polyclonal T regs failed to suppress CD4 + eT effs . These findings highlight the potential of gluten-reactive eT regs as a therapeutic for celiac disease.


  • Open Access

    Perivascular B cells link intestinal angiogenesis to immunity and to the gut-brain axis during neuroinflammation

    by Benjamin Peter, Jessica Rebeaud, Solenne Vigne, Valentine Bressoud, Nicholas Phillips, Florian Ruiz, Tatiana V. Petrova, Jeremiah Bernier-Latmani, Caroline Pot


  • Open Access

    Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL, and IL-6 in supporting antibody-producing cells in different tissues

    by Mahya Eslami, Sonia Schuepbach-Mallepell, Daniela Diana, Laure Willen, Christine Kowalczyk-Quintas, Chantal Desponds, Benjamin Peter, Michele Vigolo, François Renevey, Olivier Donzé, et al.

    Antibody-producing plasma cells fuel humoral immune responses. They also contribute to autoimmune diseases such as systemic lupus erythematosus or IgA nephropathy. Interleukin-6 and the tumor necrosis factor (TNF) family ligands BAFF (B cell-activating factor) and APRIL (a proliferation-inducing ligand) participate in plasma cell survival. BAFF binds to three receptors, BAFFR (BAFF receptor), TACI (transmembrane activator and CAML interactor), and BCMA (B cell maturation antigen), while APRIL binds to TACI, BCMA, and proteoglycans. However, which ligand–receptor pair(s) are required to maintain plasma cells in different body locations remains unknown. Here, by combining mouse genetic and pharmacological approaches, we found that plasma cells required BCMA and/or TACI but not BAFFR. BCMA responded exclusively to APRIL, while TACI responded to both BAFF and APRIL, identifying three self-sufficient ligand–receptor pairs for plasma cell maintenance: BAFF–TACI, APRIL–TACI, and APRIL–BCMA. Together, these actors accounted for 90% of circulating antibodies. In BAFF-ko mice, the reduction of plasma cells upon APRIL inhibition indicated that APRIL could function in the absence of BAFF–APRIL heteromers. No evidence was found that in the absence of BCMA and TACI, binding of APRIL to proteoglycans would help maintain plasma cells. IL-6, alone or together with BAFF and APRIL, supported mainly splenic plasmablasts and plasma cells and contributed to circulating IgG but not IgA levels. In conclusion, survival factors for plasma cells can vary with body location and with the antibody isotype that plasma cells produce. To efficiently target plasma cells, in particular IgA-producing ones, dual inhibition of BAFF and APRIL is required.